scispace - formally typeset
A

Adalsteinn Gunnlaugsson

Researcher at Lund University

Publications -  46
Citations -  1422

Adalsteinn Gunnlaugsson is an academic researcher from Lund University. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 15, co-authored 42 publications receiving 941 citations.

Papers
More filters
Journal ArticleDOI

Technical Note: MRI only prostate radiotherapy planning using the statistical decomposition algorithm

TL;DR: The Statistical Decomposition Algorithm enables a highly accurate MRI only workflow in prostate radiotherapy planning and the dosimetric uncertainties originating from the SDA appear negligible and are notably lower than the uncertainties introduced by variations in patient geometry between imaging sessions.
Journal ArticleDOI

Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer

TL;DR: A strong dose-volume relationship between small bowel volume and radiation enteritis during 5-FU-OXA-based chemoradiotherapy is indicated, indicating the application of maneuvers to minimize small bowel irradiation, such as using a “belly board” or the use of IMRT technique aiming at keeping the small bowelVolume receiving more than 15 Gy under 150 cc.
Journal ArticleDOI

MR-OPERA : A Multicenter/Multivendor Validation of Magnetic Resonance Imaging-Only Prostate Treatment Planning Using Synthetic Computed Tomography Images

TL;DR: Results of the study show that the sCT conversion method can be used clinically, with minimal differences between sCT and CT dose distributions for target and relevant organs at risk, and that an MR imaging-only workflow using MriPlanner is robust for a variety of field strengths, vendors, and treatment techniques.
Journal ArticleDOI

Krabbamein í ristli og endaþarmi - yfirlitsgrein

TL;DR: Surgery, radiation therapy and chemotherapy are the key components of rectal cancer therapy and selected patients with recurrent and metastatic disease can be salvaged with surgery but chemotherapy remains the mainstay of therapy for advanced colorectal cancer.